

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: FANG *et al.*

Application No.: To be assigned
(Division of Appl. No. 09/640,725)

Group Art Unit: 1614

Examiner: W. Jarvis

Filed: Concurrently herewith

Attorney Docket No.: 4821-439

For: BUPROPION METABOLITES AND
METHODS OF THEIR SYNTHESIS
AND USE

PRELIMINARY AMENDMENT

Box Patent Application

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants request that the following amendments and remarks be considered by the Examiner and entered into the file of the application.

IN THE CLAIMS

Please cancel claims 8-18 without prejudice.

IN THE SPECIFICATION

Please delete lines 4-7 of the specification and add the following paragraph:

--This is a division of application no. 09/640,725, filed August 18, 2000, which is a continuation-in-part of application no. 09/510,241, filed February 22, 2000, which claims the benefit of provisional application nos. 60/122,277, filed March 1, 1999 and 60/148,324, filed August 11, 1999, each of which is incorporated herein by reference.--

REMARKS


Claims 1-7 and 20-126 appear in this application for the Examiner's review and consideration. Claims 8-18 have been canceled without prejudice.

The specification has been amended to recite the priority information of the present application.

No fee is believed due for this submission. Should any additional fees be required, however, please charge such fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: November 16, 2001


Dean L. Fanelli 48,907
(Reg. No.)

For: Anthony M. Insogna (Reg. No.: 35,203)
PENNIE & EDMONDS LLP
1667 K Street, N.W.
Washington, DC 20006
(202) 496-4400